Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:IMMP NASDAQ:NMRA NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$0.70-0.4%$0.68$0.49▼$2.75$62.52M1.89201,093 shs36,338 shsIMMPPrima BioMed$1.77-0.8%$1.72$1.32▼$2.72$259.08M1.66165,186 shs42,946 shsNMRANeumora Therapeutics$1.57-5.4%$1.19$0.61▼$17.19$254.76M2.912.15 million shs437,664 shsSGMTSagimet Biosciences$9.12+1.8%$7.85$1.73▼$11.41$278.18M3.371.12 million shs290,696 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics+2.94%-15.66%+6.87%-9.44%-68.47%IMMPPrima BioMed+2.30%+1.14%+4.09%-7.77%+0.56%NMRANeumora Therapeutics+0.61%-24.20%+104.69%+156.17%-86.12%SGMTSagimet Biosciences+6.04%-3.34%+10.01%+168.26%+208.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTXContext Therapeutics2.6191 of 5 stars3.63.00.00.00.61.71.3IMMPPrima BioMed1.4825 of 5 stars3.52.00.00.01.90.00.0NMRANeumora Therapeutics2.611 of 5 stars3.13.00.00.01.12.51.3SGMTSagimet Biosciences3.1574 of 5 stars3.54.00.00.02.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 3.17Buy$5.50689.10% UpsideIMMPPrima BioMed 3.00Buy$7.00296.60% UpsideNMRANeumora Therapeutics 2.22Hold$7.14354.96% UpsideSGMTSagimet Biosciences 3.00Buy$26.83194.23% UpsideCurrent Analyst Ratings BreakdownLatest CNTX, SGMT, IMMP, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.007/16/2025NMRANeumora TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.006/26/2025CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.006/6/2025SGMTSagimet BiosciencesJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $27.005/13/2025NMRANeumora TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/8/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$1.27 per shareN/AIMMPPrima BioMed$5.14M50.41N/AN/A$1.05 per share1.68NMRANeumora TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ASGMTSagimet Biosciences$2M139.86N/AN/A$5.08 per share1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$26.73M-$0.31N/AN/AN/AN/A-29.78%-29.08%8/6/2025 (Estimated)IMMPPrima BioMed-$28.01MN/A0.00N/AN/AN/AN/AN/A8/29/2025 (Estimated)NMRANeumora Therapeutics-$243.79M-$1.61N/AN/AN/AN/A-84.79%-77.57%8/6/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.76N/AN/AN/AN/A-35.21%-34.09%8/13/2025 (Estimated)Latest CNTX, SGMT, IMMP, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SGMTSagimet Biosciences-$0.57N/AN/AN/AN/AN/A8/6/2025Q2 2025CNTXContext Therapeutics-$0.06N/AN/AN/AN/AN/A8/6/2025Q2 2025NMRANeumora Therapeutics-$0.38N/AN/AN/AN/AN/A5/14/2025Q1 2025CNTXContext Therapeutics-$0.05-$0.05N/A-$0.05N/AN/A5/12/2025Q1 2025NMRANeumora Therapeutics-$0.40-$0.42-$0.02-$0.42N/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A48.8148.81IMMPPrima BioMedN/A18.86N/ANMRANeumora TherapeuticsN/A8.988.98SGMTSagimet BiosciencesN/A20.3420.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%IMMPPrima BioMed2.32%NMRANeumora Therapeutics47.65%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics3.04%IMMPPrima BioMed3.07%NMRANeumora Therapeutics26.80%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics789.70 million86.98 millionNot OptionableIMMPPrima BioMed2,021146.79 million142.28 millionOptionableNMRANeumora Therapeutics108161.75 million118.40 millionOptionableSGMTSagimet Biosciences830.67 million26.17 millionOptionableCNTX, SGMT, IMMP, and NMRA HeadlinesRecent News About These CompaniesSagimet Biosciences (SGMT) Projected to Post Earnings on WednesdayAugust 6 at 4:54 AM | marketbeat.comSagimet Biosciences Inc. to Participate in Canaccord Genuity 45th Annual Growth Conference on August 13, 2025August 5 at 7:19 AM | quiverquant.comQSagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth ConferenceAugust 5 at 7:00 AM | globenewswire.comAnalysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $26.83July 29, 2025 | americanbankingnews.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by AnalystsJuly 26, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at Canaccord Genuity GroupJuly 25, 2025 | marketbeat.comSagimet gains as Canaccord Genuity starts with Buy on potential against MASHJuly 24, 2025 | msn.comSagimet Biosciences Inc. (NASDAQ:SGMT) Insider Eduardo Bruno Martins Sells 8,277 SharesJuly 24, 2025 | marketbeat.comInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) General Counsel Sells 10,780 Shares of StockJuly 24, 2025 | marketbeat.comInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) CEO Sells 65,478 Shares of StockJuly 24, 2025 | marketbeat.comInsider Selling: Sagimet Biosciences Inc. (NASDAQ:SGMT) Insider Sells 8,277 Shares of StockJuly 24, 2025 | insidertrades.comSagimet Biosciences (NASDAQ:SGMT) Trading Up 8.7% - Here's WhyJuly 23, 2025 | marketbeat.comWe Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business GrowthJuly 16, 2025 | finance.yahoo.comSGMT Sagimet Biosciences Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comSagimet Biosciences Inc News (SGMT) - Investing.comJune 27, 2025 | investing.comSagimet Biosciences Inc. (SGMT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comSagimet Biosciences Inc.June 14, 2025 | wsj.comSagimet Biosciences updates executive compensationJune 12, 2025 | investing.comWhat Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?June 11, 2025 | zacks.comSagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to ...June 11, 2025 | morningstar.comMWall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should KnowJune 9, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTX, SGMT, IMMP, and NMRA Company DescriptionsContext Therapeutics NASDAQ:CNTX$0.70 0.00 (-0.43%) As of 02:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Prima BioMed NASDAQ:IMMP$1.76 -0.02 (-0.84%) As of 02:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Neumora Therapeutics NASDAQ:NMRA$1.58 -0.09 (-5.12%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Sagimet Biosciences NASDAQ:SGMT$9.12 +0.16 (+1.79%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX Up Nearly 300% in 2 Years, It’s Not Too Late to Buy Mercado Libre Palantir Stock Soars After Blowout Earnings Report Caterpillar Can (and Will) Crawl Higher: Buy It on the Dip Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
